Arcadia Biosciences, Inc.
RKDA
$3.12
-$0.28-8.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.46M | 1.20M | 1.22M | 1.54M | 1.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.46M | 1.20M | 1.22M | 1.54M | 1.31M |
| Cost of Revenue | 833.00K | 682.00K | 695.00K | 1.05M | 643.00K |
| Gross Profit | 622.00K | 518.00K | 521.00K | 484.00K | 663.00K |
| SG&A Expenses | 2.12M | 1.74M | 2.65M | 2.24M | 2.68M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.96M | 2.42M | 3.34M | 3.30M | 3.33M |
| Operating Income | -1.50M | -1.22M | -2.13M | -1.76M | -2.02M |
| Income Before Tax | -4.46M | 2.60M | -4.03M | -1.18M | 1.85M |
| Income Tax Expenses | -- | -- | 8.00K | -- | -- |
| Earnings from Continuing Operations | -4.46M | 2.60M | -4.04M | -1.18M | 1.85M |
| Earnings from Discontinued Operations | -- | -- | -27.00K | -430.00K | -789.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.46M | 2.60M | -4.06M | -1.61M | 1.06M |
| EBIT | -1.50M | -1.22M | -2.13M | -1.76M | -2.02M |
| EBITDA | -1.49M | -1.21M | -2.10M | -1.75M | -1.99M |
| EPS Basic | -3.26 | 1.90 | -2.98 | -1.18 | 0.78 |
| Normalized Basic EPS | -2.50 | 0.39 | -1.77 | -0.54 | -0.99 |
| EPS Diluted | -3.26 | 1.90 | -2.98 | -1.18 | 0.33 |
| Normalized Diluted EPS | -1.31 | 0.39 | -1.77 | -0.54 | -0.42 |
| Average Basic Shares Outstanding | 1.37M | 1.37M | 1.37M | 1.36M | 1.36M |
| Average Diluted Shares Outstanding | 2.60M | 1.37M | 1.37M | 1.36M | 3.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |